Brexu‑cel gets full approval

Brexucabtagene autoleucel, a personalized cell therapy sold as Tecartus, won full United States approval on April 2 for adults with relapsed or refractory mantle cell lymphoma. (gilead.com) The Food and Drug Administration had first cleared the treatment for this lymphoma under accelerated approval on July 24, 2020. The new action converts that conditional status to traditional approval. (fda.gov) (gilead.com) Brexucabtagene autoleucel is a chimeric antigen receptor T-cell therapy, which means doctors collect a patient’s own immune cells, reprogram them to recognize the CD19 marker on lymphoma cells, and infuse them back. The current label says the product is for adults with relapsed or refractory mantle cell lymphoma and lists cytokine release syndrome and neurologic toxicities in a boxed warning. (dailymed.nlm.nih.gov) The confirmatory evidence came from cohort 3 of the ZUMA-2 study, which tested the therapy in patients whose mantle cell lymphoma had returned after one or more prior lines of treatment and who had not yet received a Bruton tyrosine kinase inhibitor. Kite said the Food and Drug Administration used efficacy, safety, and pharmacokinetic data from that cohort in the full approval. (gilead.com) (ashpublications.org) In the March 19, 2026 Blood report on ZUMA-2 cohort 3, 95 patients enrolled and 86 received the infusion. The objective response rate was 91%, the complete response rate was 73%, and the estimated 12-month progression-free survival and overall survival rates were 75% and 90%. (ashpublications.org) The earlier ZUMA-2 cohort that supported the 2020 approval showed similarly high activity after heavier prior treatment. At a median follow-up of 35.6 months, investigators reported a 91% objective response rate, a 68% complete response rate, and median overall survival of 46.6 months in 68 treated patients. (ascopubs.org) Mantle cell lymphoma is rare, making up about 3% to 6% of non-Hodgkin lymphoma cases, and it is usually aggressive once it relapses. Kite said about 33,000 people worldwide are diagnosed each year and that the disease predominantly affects men older than 60. (pmc.ncbi.nlm.nih.gov) (gilead.com) The safety discussion has stayed central because this therapy can trigger severe immune reactions and leave patients vulnerable to infections. The prescribing information says not to give Tecartus to patients with active infection or inflammatory disorders, and real-world United Kingdom data found non-relapse mortality was mostly attributable to infection. (dailymed.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov) That mix of durable responses and intensive monitoring is what the April 2026 decision locks in. For patients whose mantle cell lymphoma has come back, Tecartus now sits on a full approval rather than a provisional one. (gilead.com)